Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe?

被引:1
作者
Glynne-Jones, Robert [1 ,2 ,3 ]
Mawdsley, Suzannah [4 ]
机构
[1] Watford Dist Gen Hosp, London, England
[2] Barnet Gen Hosp, London, England
[3] Mt Vernon Canc Ctr, London, England
[4] Mt Vernon Hosp, London, England
来源
NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 12期
关键词
anal cancer; chemoradiotherapy; neoadjuvant; primary treatment; squamous-cell carcinoma;
D O I
10.1038/ncponc1258
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This Practice Point commentary discusses the findings of the Intergroup RTOG 98-11 trial, which aimed to investigate both the potential role of cisplatin as neoadjuvant chemotherapy, and also its role concurrently in combination with radiotherapy, for anal-canal carcinoma. Although chemoradiotherapy has had an important effect on the treatment of anal cancer, and allows preservation of anorectal function with survival rates similar to or better than those of surgical treatment, overall survival rates for advanced tumors are still in the region of 50-60% at 5 years. A strong theoretical rationale for cisplatin-based treatment in anal cancer exists; several phase II trials have demonstrated a high response rate with reduced colostomy rates. The Intergroup results are disappointing in that neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, followed by cisplatin-based chemoradiotherapy did not improve overall survival, disease-free survival and locoregional control when compared with the standard treatment of combined 5-fluorouracil and mitomycin chemoradiotherapy.
引用
收藏
页码:692 / 693
页数:2
相关论文
共 8 条
[1]   Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal - A randomized controlled trial [J].
Ajani, Jaffer A. ;
Winter, Kathryn A. ;
Gunderson, Leonard L. ;
Pedersen, John ;
Benson, Al B., III ;
Thomas, Charles R., Jr. ;
Mayer, Robert J. ;
Haddock, Michael G. ;
Rich, Tyvin A. ;
Willett, Christopher .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (16) :1914-1921
[2]  
Arnott SJ, 1996, LANCET, V348, P1049
[3]   Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups [J].
Bartelink, H ;
Roelofsen, F ;
Eschwege, F ;
Rougier, P ;
Bosset, JF ;
Gonzalez, DG ;
Peiffert, D ;
vanGlabbeke, M ;
Pierart, M .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2040-2049
[4]   Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study [J].
Flam, M ;
John, M ;
Pajak, TF ;
Petrelli, N ;
Myerson, R ;
Doggett, S ;
Quivey, J ;
Rotman, M ;
Kerman, H ;
Coia, L ;
Murray, K .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) :2527-2539
[5]   Neoadjuvant cisplatin chemotherapy before chemoradiation: A flawed paradigm? [J].
Glynne-Jones, Rob ;
Hoskin, Peter .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5281-5286
[6]   ACT II: The second UK phase III anal cancer trial [J].
James, R ;
Meadows, H ;
Wan, S .
CLINICAL ONCOLOGY, 2005, 17 (05) :364-366
[7]   Induction therapy for poor-prognosis anal canal carcinoma: A phase II study of the cancer and leukemia group B (CALGB 9281) [J].
Meropol, Neal J. ;
Niedzwiecki, Donna ;
Shank, Brenda ;
Colacchio, Thomas A. ;
Ellerton, John ;
Valone, Frank ;
Budinger, Susan ;
Day, Jeannette M. ;
Hopkins, Judy ;
Tepper, Joel ;
Goldberg, Richard M. ;
Mayer, Robert J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) :3229-3234
[8]  
Peiffert D, 2005, EJC SUPPL, V3, P172